Two Sigma Advisers LP Has $10.22 Million Stock Position in The Chemours Company (NYSE:CC)

Two Sigma Advisers LP raised its holdings in The Chemours Company (NYSE:CC - Free Report) by 9.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 503,100 shares of the specialty chemicals company's stock after purchasing an additional 43,200 shares during the period. Two Sigma Advisers LP owned about 0.34% of Chemours worth $10,223,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Matrix Trust Co bought a new position in Chemours during the 3rd quarter worth $25,000. Blue Trust Inc. grew its position in shares of Chemours by 166.9% during the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock worth $26,000 after acquiring an additional 731 shares during the last quarter. Truvestments Capital LLC acquired a new stake in shares of Chemours in the 3rd quarter worth about $35,000. Brooklyn Investment Group bought a new stake in Chemours in the 3rd quarter valued at about $37,000. Finally, Signaturefd LLC boosted its stake in Chemours by 163.7% during the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company's stock valued at $40,000 after purchasing an additional 1,216 shares during the period. 76.26% of the stock is currently owned by institutional investors.

Chemours Stock Down 2.5 %

Shares of CC stock traded down $0.55 on Tuesday, reaching $21.17. 2,353,165 shares of the company's stock traded hands, compared to its average volume of 1,575,809. The Chemours Company has a 12-month low of $15.10 and a 12-month high of $32.70. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The company has a market capitalization of $3.16 billion, a P/E ratio of 43.44 and a beta of 1.80. The business's 50 day moving average price is $19.90 and its two-hundred day moving average price is $20.95.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating analysts' consensus estimates of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The firm had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.44 billion. During the same quarter in the previous year, the company posted $0.64 earnings per share. The business's quarterly revenue was up .9% compared to the same quarter last year. On average, equities analysts forecast that The Chemours Company will post 1.35 earnings per share for the current year.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be given a $0.25 dividend. The ex-dividend date is Friday, November 15th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 4.72%. Chemours's dividend payout ratio is currently 200.00%.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Royal Bank of Canada reduced their price target on Chemours from $28.00 to $25.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group reduced their price objective on shares of Chemours from $29.00 to $23.00 and set a "neutral" rating for the company in a report on Tuesday, September 3rd. BMO Capital Markets raised their target price on shares of Chemours from $30.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, October 7th. Morgan Stanley dropped their price target on shares of Chemours from $30.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Tuesday, November 5th. Finally, Barclays increased their price objective on shares of Chemours from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, Chemours currently has an average rating of "Hold" and an average target price of $24.88.

Insiders Place Their Bets

In related news, SVP Alvenia Scarborough sold 7,500 shares of the business's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the completion of the transaction, the senior vice president now owns 16,645 shares of the company's stock, valued at approximately $343,552.80. The trade was a 31.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.47% of the company's stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.